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1. Introduction 
1.1 Clinical features and tumor spectrum 
Lynch syndrome (LS) (MIM No. 120435-6), previously known as hereditary nonpolyposis 
colorectal cancer (HNPCC) (Boland, 2005), is an autosomal dominant disorder caused by 
germline mutation in one of the DNA mismatch repair (MMR) genes. LS is among the most 
prevalent cancer syndromes in man and is estimated to account for 1-6% of all colorectal 
cancers (Lynch & de la Chapelle, 2003).  
Before the discovery of DNA MMR gene defects responsible for LS in the 1990s, clinical 
diagnostic criteria known as the Amsterdam I criteria (Vasen et al., 1991) were used to 
identify families likely to represent LS. The original criteria were based on colorectal cancer 
only and were subsequently modified to include extracolonic cancers as well (Amsterdam II 
criteria, Vasen et al., 1999 (Table 1). Amsterdam II criteria include colorectal cancer, cancer 
of the endometrium, small bowel, ureter, and renal pelvis as unequivocal manifestations of 
the syndrome. Later experience incorporating epidemiological, clinical, and molecular 
information has resulted in the expansion of the list of LS-associated tumors. The revised 
Bethesda criteria (Umar et al., 2004) include, among others, brain tumors as LS-related 
tumors (Table 1). Individuals that meet at least one of the Bethesda criteria are considered to 
have suspected LS, and investigating tumors for microsatellite instability (MSI) is warranted 
as a pre-screening method prior to germline mutation testing. Currently, the definition of LS 
is a molecular one and the term LS is restricted to families with an identified pathogenic 
germline mutation in one of the DNA MMR genes (Boland, 2005). 
Carriers of a pathogenic DNA MMR gene mutation have a lifetime risk of 10-53% for 
developing colorectal carcinoma, 15-44% for developing endometrial carcinoma, and less 
than 15% for other cancers (Aarnio et al., 1999; Watson & Lynch, 2001; Chen et al., 2006; 
Senter et al., 2008; Baglietto et al., 2010). The risk of developing cancer depends on the 
predisposing gene, gender and environmental factors. According to Vasen et al. (2001), the 
cumulative risk of developing brain tumor by 70 years is 1.2% in MSH2 mutation carriers 
and lower in MLH1 mutation carriers. Even if the life-time risk of brain tumor, compared to 
many other tumors, is low in LS families, the risk of brain tumors is unequivocally elevated 
compared to the general population; the calculated fold increase varies between 4 and 6 
(Aarnio et al., 1999; Vasen et al., 1996).  
Colorectal carcinomas in LS are often diagnosed at an early age (mean, 45-50 years) and the 
same applies to many extracolonic tumors, at least when compared to the corresponding 
sporadic tumors (Vasen, 2005). In published series of LS-associated brain tumors (mainly 
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representing MLH1 or MSH2 mutation carriers), the average age at diagnosis ranges from 
33 to 53 years (Vasen et al., 1996; Aarnio et al., 1999; Vasen et al., 2001; Gylling et al., 2008). 
LS-associated brain tumors may be of diverse histological types, the most common ones 
being glioblastoma (Aarnio et al., 1999) and astrocytoma (Vasen et al., 1996).  
 
Amsterdam criteria II 
 
There should be at least three relatives with a Lynch syndrome-associated cancer (colorectal 
cancer (CRC), cancer of the endometrium, small bowel, ureter or renal pelvis): all of the 
following criteria should be present: 
1)  one should be a first degree relative of the other two; 
2)  at least two successive generations should be affected; 
3)  at least one should be diagnosed before age 50; 
4)  familial adenomatous polyposis should be excluded in the CRC case (s) if any; 
5)  tumors should be verified by pathological examination 
 
Revised Bethesda criteria 
 
1) Colorectal cancer diagnosed in a patient <50 y of age. 
2) Presence of synchronous, metachronous colorectal, or other Lynch syndrome-related 
tumors*, regardless of age. 
3) Colorectal cancer with MSI-H phenotype diagnosed in a patient < 60 y of age. 
4) Patient with colorectal cancer and a first-degree relative with a Lynch syndrome-related 
tumor, with one of the cancers diagnosed under age 50 y. 
5) Patient with colorectal cancer with two or more first-degree or second-degree relatives 
with a Lynch syndrome-related tumor, regardless of age. 
 
*Lynch syndrome related tumors include colorectal, endometrial, stomach, ovarian, 
pancreas, ureter, renal pelvis, biliary tract, and brain tumors, sebaceous gland adenomas, 
keratoacanthomas and carcinoma of the small bowel.   
Table 1. Amsterdam II and revised Bethesda criteria 
The clinical features of LS variants in which the risk of brain tumor is considerably higher 
than in classical LS, namely Turcot syndrome (TS) and constitutional mismatch repair 
deficiency syndrome (CMMR-D), will be described in section “The association of brain 
tumors with hereditary cancer syndromes” below. 
1.2 Genetic basis 
Predisposition to LS is caused by heterozygous germline mutations in one of four, possibly five 
genes with verified or putative DNA mismatch repair function, namely MLH1 (MutL 
homologue 1), MSH2 (MutS homologue 2), MSH6 (MutS homologue 6), PMS2 (Postmeiotic 
segregation 2), and possibly MLH3 (MutL homologue 3). The great majority of the presently 
known 3000 unique mutations and variants in MMR genes affect MLH1 and MSH2, with fewer 
changes in MSH6, PMS2 and MLH3 (http://www.insight-group.org; Peltomaki & Vasen, 2004; 
Woods et al., 2007). Most MSH2 and MLH1 mutations are truncating (Peltomaki & Vasen, 2004; 
Woods et al., 2007) and result in unstable mRNA and protein. However, one-third of MMR gene 
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alterations are of missense type and such changes may occasionally complicate the interpretation 
of immunohistochemical analyses of tumor tissues by leading to stable but non-functional 
protein. PMS2 and MSH6 mutations in particular may carry a high risk of brain tumors, but - 
because of reduced penetrance - mainly when biallelic (CMMR-D) (Wimmer & Etzler, 2008). 
The mechanism behind constitutional inactivation of a MMR gene is not always genetic 
(point mutation or large rearrangement) but may be epigenetic (primary or secondary 
epimutation; Hitchins & Ward, 2009; Ligtenberg et al., 2009). To our knowledge, brain 
tumor has not yet been reported as part of the variable spectrum of colorectal and 
extracolonic cancers observed in constitutional epimutation carriers to date (Suter et al., 
2004; Morak et al., 2008; Hitchins & Ward, 2009; Niessen et al., 2009) but there is no reason to 
suggest why brain tumors would not develop in constitutional epimutation carriers.   
1.3 Tumorigenic mechanisms 
LS generally complies with Knudson’s two-hit mechanism of tumorigenesis (Knudson, 
1971) where germline mutation in one copy of a DNA MMR gene (first hit) causes cancer 
susceptibility but cancer initiation additionally requires the inactivation of the remaining 
wild-type copy (second hit) in a tumor progenitor cell of a somatic target tissue. Somatic loss 
of the wild-type allele, as evidenced by loss of heterozygosity (LOH), is the predominant 
mechanism of the second hit (Ollikainen et al., 2007). As a result of inactivation of both 
allelic copies, tumor tissues from LS patients typically show the absence of the respective 
MMR protein by immunohistochemical analysis (and occasionally, other MMR proteins as 
well in a defined pattern (Hendriks et al., 2006). This has been shown to apply to almost all 
colorectal carcinomas and extracolonic cancers of the LS spectrum, and brain tumors are no 
different (Gylling et al., 2008).  
Inactivation of a MMR gene is believed to initiate tumorigenesis through the failure of one 
or several essential functions that the MMR system is known to have, including repair of 
replication errors and a role in DNA damage signaling (Jiricny, 2006). Impaired repair 
capacity leads to an elevated rate of mutations in important growth-controlling genes as 
well as instability at random microsatellite sequences (“mutator phenotype”, Perucho, 1996). 
The demonstration of microsatellite instability (MSI) serves as an important biomarker for 
LS cancers. A panel of five markers (so called Bethesda panel consisting of BAT25, BAT26, 
D2S123, D5S346 and D17S250) was recommended for screening purposes (Boland et al., 
1998). Size shifts at two or more microsatellite loci indicate high-degree microsatellite 
instability (MSI-H). The mononucleotide repeats BAT26 and BAT25 are particularly 
sensitive for MSI-H in both familial and sporadic colorectal cancers, but their performance 
in extracolonic cancers is less well known. Consequently, as will be described below in 
section “The role of DNA mismatch repair defects in the pathogenesis of brain tumors”, an 
investigation of different cancers from a nationwide cohort of LS families showed that, 
despite origin from verified MMR gene mutation carriers, MSI-H frequency in tumors 
varied between 100 and 0%, where the highest frequencies were for ureter, stomach, and 
colon and the lowest frequency for brain (Gylling et al., 2008). 
2. The association of brain tumors with hereditary cancer syndromes 
2.1 Main cancer syndromes in which brain tumors are overrepresented 
Several inherited cancer predisposition syndromes are known that are associated with 
increased risk of brain tumors, besides malignancies of other organs (Table 2). Analysis of 
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germline and somatic alterations in brain tumors from such syndromes may provide 
valuable clues to the mechanisms of brain tumor development in general. In most cases, the 
predisposing gene encodes a tumor suppressor protein and the disease is dominant on 
pedigree level but recessive on cellular level.  
The list includes two syndromes that are associated with germline mutation in DNA MMR 
genes. Co-occurrence of brain tumor with colorectal tumor in the same individual is known 
as Turcot syndrome (TS) (Turcot et al., 1959). TS can be dominant or recessive. Dominant TS 
is due to heterozygous mutations in DNA MMR genes (Chan et al., 1999; Lebrun et al., 2007) 
or the Adenomatous Polyposis Coli (APC) gene (Foulkes, 1995). Recessive TS is due to 
biallelic mutation in DNA MMR genes (De Rosa et al., 2000; Miyaki et al., 2001; Hegde et al., 
2005) and can also be classified under CMMR-D (but not vice versa: only a minority of 
CMMR-D cases fulfill the diagnostic criteria of TS). The predominant brain tumor in APC-
associated TS is medulloblastoma whereas glioblastoma predominates in TS associated with 
DNA MMR gene mutations (Hamilton et al., 1995).  
To date, some 100 patients have been reported who are homozygotes or compound 
heterozygotes for DNA MMR gene mutations. The term “constitutional mismatch repair 
deficiency” (CMMR-D) (Wimmer & Etzler, 2008) or “Lynch III” (Felton et al., 2007) has been 
proposed for such cases. The clinical picture is severe: the patients are affected by 
hematological malignancy or brain tumor in childhood and those who survive their first 
tumor are at risk to develop colorectal cancer or other typical LS-associated malignancy in 
adolescence or early adulthood (Wimmer & Etzler, 2008). The predominant type of brain 
tumor that develops in CMMR-D is astrocytoma, primarily glioblastoma (Wimmer & Etzler, 
2008). The prevalence of hematological tumors may be higher in patients with biallelic 
MLH1 or MSH2 mutations whereas patients with MSH6 or PMS2 mutations have a higher 
risk of brain and LS-associated tumors (Wimmer & Etzler, 2008).   
 
              
  Predisposing Mode of Characteristic type   
Syndrome gene   inheritance of brain tumor   
Li-Fraumeni TP53   AD Astrocytoma,    
        choroid plexus tumor   
Neurofibromatosis, type 1 NF1   AD Optic pathway glioma   
Neurofibromatosis, type 2 NF2   AD Vestibular schwannoma, 
        meningioma   
Von Hippel-Lindau VHL   AD Hemangioblastoma   
Tuberous sclerosis TSC1, TSC2 AD Subependymomal giant 
        cell astrocytoma   
Gorlin  PTCH   AD Medulloblastoma   
Turcot APC   AD Medulloblastoma   
  MSH2, MLH1, AD or AR Glioblastoma   
  MSH6, PMS2         
Constitutional MMR MSH2, MLH1, AR Astrocytoma (glioblastoma) 
deficiency MSH6, PMS2         
AD, autosomal dominant, AR, autosomal recessive. 
Table 2. Inherited cancer predisposition syndromes that are associated with increased risk to 
brain tumors, in addition to malignacies of various organs. 
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2.2 Molecular characteristics of “syndromic” brain tumors 
As evident from Table 2, inherited syndromes are often associated with particular types of 
brain tumor (Ullrich, 2008). This is likely to reflect a combination of germline and somatic 
effects. Locus or allelic heterogeneity may explain some of the increased brain tumor risk in 
certain families. As mentioned above, among MMR genes, PMS2 mutations in particular 
(and when biallelic) are associated with increased brain tumor risk (Wimmer & Etzler, 2008). 
Germline mutation in TP53 predisposes to Li-Fraumeni syndrome, and especially families 
with TP53 missense mutations within the core DNA binding domain suffer from brain 
tumors (Birch et al., 1994). Some germline mutations may have tissue-specific effects that are 
mediated by unique mechanisms. For example, the tetramerization domain of the protein 
product of the R337H mutation in TP53, which is enriched in Brazil, was found to be less 
stable than that of wild-type p53 and therefore sensitive to disruption at acidic pH 
(DiGiammarino et al., 2002). This was proposed as an explanation for the frequent 
occurrence of adrenocortical carcinoma in association with this mutation.   
Even in families segregating an identical germline mutation, tumors at different anatomical sites 
and at different ages develop, as observed in LS/TS (Peltomaki et al., 2001) or Li-Fraumeni 
syndrome (Malkin, 2004). This has prompted investigators to search for additional germline 
genetic variations or modifier genes. In carriers of TP53 mutation and especially those of them 
who were clinically affected, copy number variation frequencies in the germline were found to 
be significantly elevated compared to healthy controls (Shlien et al., 2008). Moreover, in choroid 
plexus tumors, germline hemizygous deletions had progressed into homozygous deletions and 
germline duplications had enlarged in size. It was suggested that in association with 
constitutional dysfunction of TP53, germline copy number variations may provide a foundation 
for the development of more striking chromosomal changes in tumors (Shlien et al., 2008). 
Inherited MMR deficiency could in theory have analogous effects on other genes by causing 
subtle genetic instability (Fodde & Smits, 2002), although it is yet to be proven.  
Compatible with tumor suppressor function and Knudson’s two-hit hypothesis, the wild-type 
allele of the predisposing genes of the syndromes listed in Table 2 is regularly inactivated in 
tumors, as shown for MMR genes in TS (Chan et al., 1999; Lebrun et al., 2007), APC in TS 
(Hamilton et al., 1995), and TP53 in Li-Fraumeni syndrome (Rieber et al., 2009; Seidinger et al., 
2010). In the case of MMR genes, inactivation of both copies in a target tissue typically, but not 
always, results in MSI and a generalized “mutator” phenotype (Gylling et al., 2008). As will be 
discussed in greater detail below under “The role of DNA mismatch repair defects in the 
pathogenesis of brain tumors”, brain tumors may constitute an important exception to the 
general rule. Apart from the inactivation of the alleles of the predisposing gene, additional 
somatic changes in tumor tissues may make a difference. In TS patients with (heterozygous) 
germline mutation in MSH2, TP53 inactivation and chromosomal instability were found to be 
required for the genesis of glioblastoma but not for colorectal carcinoma, which in turn seemed 
to require TGFβRII frameshift mutation (Leung et al., 2000).  
3. The role of DNA mismatch repair defects in the pathogenesis of brain 
tumors 
3.1 Sporadic brain tumors 
With some exceptional single reports (Alonso et al., 2001), MSI is generally rare in brain tumors 
regardless of histology (Table 3). This is true especially when using microsatellite markers 
recommended for the analysis of colorectal cancers (like the Bethesda panel, Boland et al., 1998, 
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or panels based on mononucleotide repeats exclusively). Frequencies of MSI from studies using 
dinucleotide repeat markers alone or in combination with tri- and tetranucleotide repeat 
markers vary considerably (see e.g., Gomori et al., 2002 and Wooster et al., 1994 in Table 3).  
 
  Markers used to Status of    
  study MSI (type Frequency MMR protein    
Tumor type of repeat) of MSI expression* Reference   
Pediatric BAT25, BAT26, MSI-low (1 MSH6+ Vladimirova 
malignant MONO-27, NR-21, unstable marker): (other proteins et al., 2008   
astrocytoma NR-24 (mono) 
4/126 
(3%) 
  not studied)     
  and Penta C,    
  Penta D (penta)    
     
Three sets of BAT25, BAT26 2 unstable Not studied Alonso et al., 
tumors: (mono) markers: 2001   
 Pediatric 12/45 (27%)    
grade III & IV    
astrocytoma    
 Pediatric    
4/17 
(24%) 
          
ganglioglioma    
 Adult grade 0/98 (0%)    
III & IV     
astrocytoma    
     
Two sets of BAT25, BAT26, MSI-high (> 2/3 Eckert et al., 
tumors: CAT25 (mono) markers unstable): 2007   
 Pediatric high- 0/71 (0%) MSH2+, MSH6+    
grade glioma in all    
 Adult high- 1/619 (0.16%) MSH2-, MSH6-    
grade glioma in the MSI-high    
  tumor    
     
Glioma DCC, D9S171, 1 unstable marker: Not studied Gomori   
  D10S541, D13S121, 4/7 (57%) (no mutation in et al., 2002   
  D17S520, D19S412 2 unstable markers: MLH1 or MSH2)    
  (di) and AR (tri) 2/7 (29%)    
     
Glial and other vWFa, vWFb, 1 unstable marker: Not studied Wooster   
brain tumors DXS981 (tetra) 1/54 (1.9%) et al., 1994   
  and AR, DM,    
  c-myc (tri) and    
  D2S123, D16S413,    
  D17S796, D16S301,    
  D16S303, D16S588    
  (di)    
Table 3. DNA mismatch repair defects in sporadic primary brain tumors. 
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  Markers used to      Status of       
  study MSI (type Frequency   MMR protein     
Tumor type of repeat)   of MSI   expression* Reference   
Medulloblastoma NR27, NR21, MSI-high (> 2 Among MSI  Viana-   
  NR24, BAT25, unstable markers): cases, MSH6+ Pereira et   
  BAT26 (mono) 1/36 (2.7%) in all (other al., 2009   
      MSI-low (1   proteins not     
      unstable marker): studied) and     
      3/36 (8.3%) MSH6 promoter     
          methylation     
          in 2       
                  
Meningioma BAT25, BAT26, No unstable  Not studied Tilborg et   
(NF2 intact) BAT40, MSH6  markers in any     al., 2006   
  (mono) and  of 25 tumors         
  D2S123, D5S346             
  (di)               
*+, expressed, -, not expressed 
(Table 3., continued) 
There is often no demonstration that MSI results from defective MMR. While 
immunohistochemical studies occasionally implicate one of the MMR proteins in brain 
tumors with MSI (Eckert et al., 2007; Szybka et al., 2003), correlation between MSI and MMR 
protein expression remains poor in many cases (Szybka et al., 2003).  
Hardly any information is available of the molecular mechanisms that could lead to MMR 
protein inactivation in brain tumors. As for potential inactivating mechanisms, there is 
evidence that MSH6 is prone to promoter methylation (Viana-Pereira et al., 2009) and 
mutation (Yip et al., 2009) in sporadic brain tumors. Taken together, deficient MMR seems 
to play a less important role in brain tumors compared to e.g., sporadic colorectal cancers, 
among which 15 – 25% are MMR-deficient in virtually all published series (Peltomaki, 
2003). As will be discussed below, this does not exclude the potential importance of MMR 
protein functions other than mismatch repair in various stages of brain tumor 
development.   
3.2 Lynch syndrome-associated brain tumors 
Our recent analysis of tumors arising in different organs from LS mutation carriers showed 
that, like other tumors, brain tumors complied with Knudson’s two-hit hypothesis by 
displaying the absence of the MMR protein corresponding to the germline mutation, which 
suggests inactivation of both copies of the MMR gene in question (Gylling et al., 2008, Fig. 
1). Studies published to date report frequencies of 75 – 100% for the immunohistochemical 
loss of MMR protein(s) in brain tumors from heterozygous carriers of MMR gene mutations 
(Table 4).  
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Fig. 1. Decreased MMR protein expression corresponding to germline mutation vs. 
microsatelite instability using Bethesda markers. 
The loss of MMR protein expression may (Leung et al., 2000) or may not (Gylling et al., 
2008) lead to MSI (Table 4). Since the detection of MSI by conventional techniques requires 
the presence of at least one major tumor clone which exhibits microsatellite repeat length 
deviating from the normal allele size, the apparent absence of MSI in brain tumors may have 
an alternative explanation based on clonal heterogeneity. Our small pool PCR experiments 
of brain tumors indeed supported the hypothesis since they detected MSI but it was diluted 
by multiple minor clones with mutant allele frequency below 30% and the high proportion 
of clones with normal alleles so that the pattern by conventional PCR was microsatellite-
stable. The small pool PCR technique we applied is the same that has been used to detect 
MSI in constitutional non-neoplastic tissues from biallelic MMR gene mutation carriers in 
CMMR-D (see next section). Studies suggest that the presence of multiple subclones may be 
a general characteristic of MSI tumors from LS and sporadic settings (Fujiwara et al., 1998; 
Barnetson et al., 2000).  
Since MSI is generally uncommon in brain tumors (see previous section), its presence may 
pinpoint MMR gene germline mutation carriers (Giunti et al., 2009). In a series of 34 
pediatric gliomas of different grades, Giunti et al. (2009) found two with MSI and both 
patients subsequently revealed germline mutations in MMR genes (biallelic in one and 
monoallelic in the other case) compatible with TS. Interestingly, a clear qualitative difference 
in the MSI pattern was evident when a glioblastoma from a TS patient and a colon cancer 
from an affected relative were compared. Glioblastoma displayed smaller allelic shifts 
which may make MSI more difficult to discern and supports the idea that the type of MSI 
varies in tumors of different histological derivation as previously demonstrated for 
endometrial vs. colorectal carcinomas representing LS (Kuismanen et al., 2002) and sporadic 
cases (Duval et al., 2002). 
Not much is known about the nature of second “hits” that may mediate MMR protein 
inactivation in LS-associated brain tumors. In analogy to colon cancers in LS (Ollikainen et 
al., 2007), LOH appears to be the predominant mechanism (Gylling et al., 2008; Chan et al., 
1999) whereas promoter methylation is rare or absent (Gylling et al., 2008).   
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                Expression of   
        Markers used     protein     
        to study MSI     corresponding   
Characteristics Predisposing (type of   Frequency   to germline   
of tumor series gene   repeat)   of MSI   mutation   Reference 
TS or LS   MSH2 or   BAT26, BAT40 MSI-high   MSH2- in MSH2 Leung et 
(3 glioblastoma MLH1   (mono) and (> 2 unstable associated and  al., 2000 
multiforme, 1     TP53, D18S58, markers):   MLH1- in MLH1   
mixed glioma)     D2S123 (di) 4/4 (100%)   associated cases   
                      
LS or TS   MLH1, MSH2, BAT25, BAT26 No unstable Germline   Gylling et 
(7 brain tumors or MSH6   (mono) and marker   mutation-   al., 2008 
of various       D5S346,   in any of   associated     
histology)       D2S123,    7 tumors*   protein lost   
        D17S250 (di)     in 3/4 (75%)   
                      
TS or LS   MSH2 or   Not studied Not studied MSH2- in MSH2 Lebrun et 
(1 anaplastic MLH1           associated and al., 2007 
astrocytoma             MLH1- in MLH1   
grade III,                associated case   
1 glioblastoma)                   
                      
TS   PMS2   BAT25, BAT26, No. of unstable Not studied Giunti et  
(2 glioblastomas) (biallelic)   NR21, NR22, markers:       al., 2009 
    in one and   NR24 (mono) 3/3 (PMS2-       
    MLH1 (mono-     associated),       
    allelic) in       4/5 (MLH1-       
    another       associated)         
*By small-pool PCR using D5S346 and D2S123, MSI was present in 4/4 tumors tested. 
Table 4. DNA mismatch repair defects in brain tumors from heterozygous carriers of MMR 
gene mutations, representing Lynch syndrome (LS) or Turcot syndrome (TS). 
3.3 Brain tumors in constitutional mismatch repair deficiency syndrome 
In individuals with homozygous or compound heterozygous germline mutations in MMR 
genes (CMMR-D syndrome), both alleles of a given MMR gene are inactive from birth and 
the corresponding MMR protein is absent not only in tumors but in normal tissue as well 
(Wimmer & Etzler, 2008). Since normal non-neoplastic tissues lack significant clonality 
which is a prerequisite for the detection of MSI, it is not surprising that conventional PCR 
reveals no MSI in normal tissues; however, MSI may be detectable by small-pool PCR 
(Parsons R et al., 1995). In regard to brain tumors from biallelic MMR gene mutation 
carriers, immunohistochemical studies usually show the lack of a given MMR protein, 
whereas MSI (by conventional techniques) is present in only a minority (Bougeard et al., 
2003; Agostini et al., 2005; Poley et al., 2007; Wagner et al., 2003; Hegde et al., 2005). These 
observations emphasize the special nature of brain tumors when compared to other (e.g., 
colorectal) cancers from biallelic mutation carriers. The findings raise the question whether 
other functions of the MMR proteins (Jiricny, 2006), such as impaired DNA damage 
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signaling (Agostini et al., 2005; Bougeard et al., 2003), might be more important than 
postreplicative mismatch repair in brain tumor development.  Resistance to alkylating 
agents, which develops irrespective of MSI in recurrent gliomas (Yip et al., 2009) may lend 
further support to this possibility.  
An interesting feature of CMMR-D is that almost all patients display signs of 
neurofibromatosis 1, mainly café-au-lait spots, in the absence of germline NF1 mutations. It 
was found that the NF1 gene is a mutational target in MMR-deficient cells (Wang et al., 
2003), making it possible that neurofibromatosis 1 features result from early somatic 
mutations targeting NF1. 
3.4 Therapy-induced defects in DNA mismatch repair genes 
The fact that almost all glioblastomas recur and recurrent lesions are fatal within around a 
year has prompted comparative molecular studies between primary and recurrent brain 
tumors. Taking advantage of MSI as an indicator of a tumor clone (or clones), Gomori  et al. 
(2002) found intensive clonal selection which may contribute to the recurrence of gliomas. 
Yip et al. (2009) observed that certain MSH6 mutations were selected in glioblastomas 
during temozolomide (alkylating agent) therapy and mediated temozolomide resistance, 
which may in part explain the poor survival associated with recurrent gliomas. 
Interestingly, the role of MSH6 in temozolomide response did not depend on MSI. 
4. Epigenetic alterations in brain tumors 
Distinct methylation profiles may accompany different histological types and subtypes of 
brain tumors. Studies on promoter CpG methylation of tumor suppressor and other growth-
regulatory genes have revealed patterns characteristic of astrocytoma (Yu et al., 2004), 
various glioma subtypes (Uhlmann et al., 2003), and medulloblastoma (Lindsey et al., 2005). 
Epigenetic changes may correlate with grade; for example, Uhlmann et al. (2003) found that 
pilocytic astrocytomas, which are grade I tumors, showed no CpG island hypermethylation 
of growth-controlling genes as opposed to astrocytomas, oligoastrocytomas, and 
oligodendrogliomas (grade II – III tumors) which were associated with frequent CpG island 
methylation.  
In analogy to sporadic brain tumors, LS-associated brain tumors that we investigated 
(Gylling et al., 2008, Fig. 2) may also show patterns of tumor suppressor gene promoter 
methylation characteristic of tumor type, which might become more distinct if larger 
series of brain tumors from LS patients were available for molecular studies. Furthermore, 
comparison of tumor suppressor promoter methylation profiles in brain tumors to those 
in cancers of other organs from MMR gene mutation carriers suggests the presence of 
organ-specific epigenetic patterns in carriers of even identical predisposing mutations 
(Fig. 3). 
Among 24 tumor suppressor genes tested, colorectal cancers from LS patients showed the 
highest number of methylated genes whereas brain tumors had the lowest number (Gylling 
et al., 2008). Promoter methylation is expected to silence the respective tumor suppressor 
genes and thereby promote tumor formation. The organ-specific epigenetic patterns we 
observed may thus contribute to the selective tumor spectrum in LS.  
Some epigenetic changes may predict treatment response in brain tumors. For example, the 
repair enzyme encoded by the 06-methylguanine-DNA methyltransferase (MGMT) gene 
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removes alkyl groups from guanine and thereby counteracts therapy with alkylating agents. 
If, however, MGMT is silenced by promoter methylation, chemotherapy-induced lesions 
remain unrepaired in DNA and trigger apoptosis. Promoter methylation of MGMT, which 
occurs in approximately half of gliomas, is an independent favorable prognostic sign and 
confers a significant survival benefit from temozolomide treatment (Hegi et al., 2005). 
Moreover, recent findings indicate that methylated MGMT alleles are enriched in a 
subpopulation presumed to comprise glioma-initiating cells, even when the original 
glioblastoma may have only a minority of methylated alleles (Sciuscio et al., 2011).  
Of note, besides chemotherapeutic drugs, methylated compounds may also be contained in 
food, and methylation tolerance due to MGMT inactivation by promoter methylation may 
thus have broader significance in cancer development. For example, it was proposed that 
MGMT field defect in colorectal mucosa may be an initiating event in colorectal carcinoma 
by two alternative mechanisms: first, in concert with KRAS mutation allowing a 
microsatellite-stable phenotype to become malignant and second, in concert with MMR 
deficiency facilitating the development of MSI cancers (Svrcek et al., 2010).    
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Fig. 2. Promoter methylation in 24 tumor suppressor genes studied using methylation-
specific MLPA (MS-MLPA) assay in LS brain tumors. Black boxes indicate methylation of 
the tumor suppressor gene, whereas no methylation is shown as a white box. 
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Fig. 3. Promoter methylation in Lynch syndrome patients. The height of the bar depicts 
percentage of tumors with methylation at a given gene promoter. 
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5. Concluding remarks and future directions 
As multi-organ cancer syndromes, LS and its variants TS and CMMR-D provide useful 
models to study carcinogenesis triggered by a failure in the MMR system. Genetic and 
epigenetic patterns have been revealed that may help explain the organ-specific cancer 
susceptibility in LS and more generally, the molecular pathogenesis of cancers of different 
organs. Brain tumors have drawn attention to MMR gene functions beyond the mere 
correction of replication errors. While information of the predisposing mutation has 
efficiently been translated into clinical practice and a significant decrease in mortality as a 
result of regular surveillance has been reported for LS-associated colorectal cancer (de Jong 
et al., 2006; Jarvinen et al., 2009), mortality remains high for other tumors that are too rare to 
be screened for, such as brain tumors (de Jong et al., 2006). Biomarkers that could predict 
which mutation carriers are at risk for which cancers before the actual tumor develops are 
eagerly awaited but not yet available. Much progress has been achieved in identifying 
biomarkers that may predict the behavior, prognosis, and treatment response of existing 
tumors, including those of the brain. Inherited cancer syndromes will no doubt remain 
important as shortcuts to the understanding of the molecular pathogenesis of brain and 
other tumors also in the future. Since many such syndromes are relatively rare, collaboration 
between basic, epidemiological, and clinical researchers continues to be the key to sufficient 
numbers of cases and specimens for high-quality research. 
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